Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q1 2017 · 10-Q
Revenue$9.64M$9.64M+24.5% vs Q1 2016 Net Income-$1.27M-$1.27MN/M vs Q1 2016 EPS Diluted-$0.08-$0.08N/M vs Q1 2016 Operating Income-$657,802N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
Free Cash Flowderived$1,315,426+150.4% Margins · derivedOperating margin-6.8%−0.4 pt vs Q1 2016
Net margin-13.2%−10.0 pt vs Q1 2016
ended Mar 31, 2017 · filed May 15, 2017 · 45 d after period end